Concepedia

Kjersti Davidsen

KD

Statistics

Publications

1

Citations

19

H-Index

1

Active since

2018

Affiliations

National University Cancer Institute, Singapore(Current)

Kjersti Davidsen is an author at National University Cancer Institute, Singapore specializing in t cell immunity, lung cancer, and cancer therapeutics.

Top concepts

Publications per year

2018–2018

1

Publications

1

Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.

Murray Yule, Kjersti Davidsen, Magnus Bloe et al. · Journal of Clinical Oncology · 2018 · 19 citations

, , +26

1–1 of 1